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Schizophrenia (SZ) is a chronic and severe mental illness for which currently there is no
cure. At present, the exact molecular mechanism involved in the underlying pathogenesis
of SZ is unknown. The disease is thought to be caused by a combination of genetic,
biological, psychological, and environmental factors. Recent studies have shown that
epigenetic regulation is involved in SZ pathology. Specifically, DNA methylation, one of
the earliest found epigenetic modifications, has been extensively linked to modulation
of neuronal function, leading to psychiatric disorders such as SZ. However, increasing
evidence indicates that glial cells, especially dysfunctional oligodendrocytes undergo
DNA methylation changes that contribute to the pathogenesis of SZ. This review
primarily focuses on DNA methylation involved in glial dysfunctions in SZ. Clarifying this
mechanism may lead to the development of new therapeutic interventional strategies for
the treatment of SZ and other illnesses by correcting abnormal methylation in glial cells.
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INTRODUCTION
Schizophrenia (SZ) is a chronic and severe mental illness that affects approximately 1% of the
population (Roussos andHaroutunian, 2014). This mental illness is characterized by clinical deficits
featured by socially inappropriate behaviors such as paranoia, hallucinations, and inappropriate
emotional responses. Although the pathogenesis of SZ is unknown, it has been commonly accepted
Abbreviations: Basic helix-loop-helix, bHLH; Brain derived neurotrophic factor, BDNF; Central nervous
system, CNS; 2,3-cyclicnucleotide-phosphodiesterase, CNP; Cytosine-guanine dinucleotide, CpG; Disrupted-in-
schizophrenia 1, DISC1; DNA methytransferases, Dnmts; The excitatory amino-acid transporter, EAAT; Embryonic
day 11.5, E11.5 d; Growth arrest and DNA damage 45-beta, Gadd45β; Glial fibrillary acidic protein, Gfap;
Histone deacetylases, HDACs; 5-hydroxymethylcytosine, 5hmC; Inhibitor of DNA binding 2 and 4, Id2/4; Myelin
associated glycoprotein, MAG; Methyl-CpG-binding protein 2, MeCP2; Methyl—binding domain protein, MBD; 5-
Methylcytosine, 5mC; Monocarboxylate transporter 4, MCT4; Myelin oligodendrocyte glycoprotein, MOG; Myelin-
associated oligodendrocytic basic protein, MOBP; Multiple sclerosis, MS; Neuroepithelial cells, NPCs; Neuregulin
1, NRG1; Neural stem cells, NSCs; Oligodendrocytes precursor cells, OPCs; Oligodendrocyte transcriptional factor
2, Olig2; Oligodendrocytes, OLs; Platelet derived growth factor receptor alpha, PDGFRα; Proteolipid protein, PLP;
Peripheral nervous system, PNS; Protein arginine N-methyltransferase 5, PRMT5; S-adenosyl homocysteine, SAH;
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transducer and activator of transcription 3, Stat3; Schizophrenia, SZ; The ten-eleven translocases, TETs; The tissue
plasminogen activator, tPA.
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to be caused by a combination of genetic, biological,
psychological, and environmental factors (reviewed in Akbarian,
2014; Shorter and Miller, 2015).
In the past decade, several hypotheses concerning the
pathogenesis of SZ have been raised up and tested. Among
them, dysfunction of neurotransmitters, such as dopamine,
gamma-aminobutyric acid (GABA), glutamate, as well as
5–hydroxytryptamine (5-HT) have been implicated as primary
etiologies of SZ. In general, most studies have focused on the
dysfunction of neurons in different regions of gray matter that
include the ventral tegmental portion, the limbic system and the
prefrontal cortex (Plitman et al., 2014; Taylor and Tso, 2015).
However, recent evidence has demonstrated the involvement
of glial changes in the underlying pathogenesis of SZ. For
example, in SZ, ultra-structural signs of oligodendrocyte
deficiency have been implicated in myelinated fiber damage
in gray matter (Barley et al., 2009; Williams et al., 2013b;
Hercher et al., 2014). Moreover, increasing evidence from
neural imaging, genetic analysis, post-mortem morphological,
molecular biological and pharmacological studies revealed a
wide range of white matter abnormalities such as dysfunctional
oligodendrocytes with associated myelin deficits in the patients
with SZ (Hof et al., 2002; Flynn et al., 2003; Voineskos
et al., 2013; reviewed in Nave and Ehrenreich, 2014). Evidence
has also shown that the abnormal activation of astrocytes
or microglia may also be implicated in SZ (Katsel et al.,
2011a; Frick et al., 2013). As such, glial cell dysfunction
seems to be a primary deficit in SZ, which can alter the
synaptic function and/or circuitry and cause neuronal deficits
(Stewart and Davis, 2004; Segal et al., 2007; Barley et al., 2009;
Williams et al., 2013a). Therefore, glial cells may function as
key players that drive the underlying pathology of SZ (recently
reviewed in Bernstein et al., 2015; Wang et al., 2015). The
advanced understanding of the mechanisms that regulate glial
function may provide a new insight into the development of
therapeutic intervention strategies for SZ or related mental
illnesses.
Most glial cells (i.e., astrocytes and oligodendrocytes)
are differentiated from the neural stem cells (NSCs). After
specification, glial progenitor cells/oligodendrocytes precursor
cells (OPCs) can further differentiate into oligodendroglial
lineage cells or astrocytes, and the processes are controlled
by specific transcriptional programs (de Castro et al., 2013).
Recently, studies have implicated specific epigenetic changes
to SZ pathology (reviewed in Akbarian, 2014; Shorter and
Miller, 2015). Epigenetic does not alter gene sequences but
can directly influence gene expression (reviewed in Chen and
Riggs, 2011; Smith and Meissner, 2013). For example, DNA
methylation, one of the earliest types of epigenetic modifications,
has been extensively linked to SZ (reviewed in Grayson and
Guidotti, 2013). It has been shown that DNA methylation
was correlated with oligodendrocyte dysfunction and/or myelin
deficits in the brain of patients with SZ (Iwamoto et al.,
2005, 2006; Wockner et al., 2014). Moreover, antipsychotic
drugs have been shown to be able to alter the pathological
changes associated with DNA methylation or demethylation
and are thereby thought to be beneficial in the treatment
of SZ (reviewed in Guidotti and Grayson, 2014). In this
comprehensive review, we primarily focus on the role of DNA
methylation in glial cells’ generation and aberrant methylation
involved in glial dysfunction leading to SZ and other related
illnesses.
GLIAL ABNORMALITIES IN SZ
Glial cells mainly include astrocytes, oligodendrocytes, microglia,
ependymal cells and retinal Müller cells in the central nervous
system (CNS). In addition, the term glial cells also extend
to Schwann cells and satellite cells in the peripheral nervous
system (PNS). Besides basic functions like nutritional support or
neuronal protection, glial cells have other integral roles including
governing myelination, synapse formation and immunological
reactions (Namihira and Nakashima, 2013). Increased evidence
shows that glial cells, especially oligodendrocyte dysfunction
with corresponding myelin deficits occur in the white matter
or gray matter of SZ (reviewed in Bernstein et al., 2015; Miyata
et al., 2015). Additional abnormalities have also been noted in
astrocytes and microglia (Katsel et al., 2011a; Chew et al., 2013;
Frick et al., 2013).
Oligodendroglial cells are generated from neural progenitor
cells (NPCs) in the gliogenic phase of gestation. After
specification, OPCs continued to differentiate into immature
oligodendrocytes and finally the mature oligodendrocytes (de
Castro et al., 2013). There are different oligodendrocyte markers
identifying different stages of oligodendrocytes, including
platelet derived growth factor receptor alpha (PDGFRα) for
OPCs, O4 for immature oligodendrocytes, myelin associated
glycoprotein (MAG), proteolipid protein (PLP), and myelin
basic protein (MBP) for the mature oligodendrocytes (de Castro
et al., 2013). Abnormal expression of these markers along with
some oligodendrocyte related transcription factors have been
found in SZ.
For example, PLP1 was shown to be down-regulated in
SZ. It is believed that genetic polymorphisms of PLP1 in
males are likely to cause an increased susceptibility to SZ
(Qin et al., 2005). Similarly, a genetic association of the 2,3-
cyclicnucleotide-phosphodiesterase (CNP) andMAG genes were
also found in SZ (Wan et al., 2005; Yang et al., 2005). The
CNP risk polymorphism was associated with down-regulation
of gene expression in SZ (Peirce et al., 2006). Other studies
have shown that although the expression of MAG, CNP
and oligodendrocyte transcriptional factor 2 (Olig2) in the
gray or white matter did not differ between SZ patients
and normal controls, myelin-associated oligodendrocytic basic
protein (MOBP) mRNA levels were increased in the white
matter of patients with SZ (Usui et al., 2006). The myelin
oligodendrocyte glycoprotein (MOG) gene is considered to
be a key biological target for SZ due to its association with
white matter abnormalities and its importance in mediating the
complement cascade (Zai et al., 2005). Some oligodendrocyte
related transcriptional factors, such as Olig2, a basic helix-loop-
helix (bHLH) oligodendrocyte transcription factor, together with
Olig1, are required for normal oligodendrocyte development and
functioning. Genetic association analysis showed that variations
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in oligodendrocyte transcription factor Olig2 together with
Olig1 result in abnormal oligodendrocyte development and
functioning, thereby enhancing susceptibility to SZ (Georgieva
et al., 2006; Prata et al., 2013). Another target factor called sex-
determining region Y-box contains gene 10 (Sox10), has also
been shown to be responsible for the terminal differentiation
of oligodendrocytes by combining with Olig1/2 (Li et al., 2007;
Küspert et al., 2011). The abnormal expression of Sox10 has
also been found to be associated with SZ (Iwamoto et al.,
2005).
Moreover, Disrupted-in-schizophrenia 1 (DISC1) has
also been cited as a strong candidate target gene for SZ.
Rationale involving its implication in SZ revolves around
the ability of DISC1 to negatively regulate the differentiation
of oligodendrocytes (Katsel et al., 2011b; Boyd et al., 2015).
The neuregulin 1 (NRG1)/ErbB signaling pathway is one
of the important pathways responsible for the regulation of
myelination (Tao et al., 2009). Henceforth, it was also considered
as a key target for intervention to assist the treatment for
SZ (Alaerts et al., 2009). Moreover, recent evidence suggests
a key role of astrocytes in SZ due to their ability to interact
with neurons, and function in the maintenance of glutamate
homeostasis and recycling. The expression of astrocytic genes
such as S100 beta (S100β), diodinase type II, aquaporin-4,
glutaminase, excitatory amino-acid transporter 2 (EAAT2) and
thrombospondin are significantly reduced in the deep layers of
the anterior cingulate gyrus in patients with SZ (Katsel et al.,
2011a). In addition, post-mortem and imaging studies have
also suggested a critical role for microglial activation in the
underlying pathogenesis of SZ patients (Frick et al., 2013). As
such, these recent findings suggest that glial dysfunction may
be involved in the underlying pathogenesis of SZ. However, the
exact molecular mechanisms underlying the pathological process
are currently unknown.
DNA Methylation
DNA methylation is one of the earliest found epigenetic
modifications thought to drive the pathology of various
psychiatric diseases such as SZ (Grayson and Guidotti, 2013;
Numata et al., 2014). It is mediated by DNA methytransferases
(Dnmts), which can transfer a methyl group (CH3) from
S-adenosyl-L-methionine (SAM) to the fifth carbon position of
cytosine. The methylated cytosine at fifth carbon position
is named 5-methylcytosine (5mC). During the methylation
process, Dnmts transfer the methyl group from SAM to cytosine
residues, generating S-adeno-sylhomocysteine (SAH; reviewed
in Smith and Meissner, 2013). In general, the methyl-binding
domain proteins (MBDs) recruit histone deacetylase (HDACs)
and co-repressors (co-rep) by Dnmts to form transcription
repressor complexes. By forming the complexes, they prevent
transcription factors from binding with their specific DNA
sequences, causing silence or inhibition of gene expression
(reviewed in Smith and Meissner, 2013; Figure 1). There are
six members belonging to the MBD family, including MBD1–4,
MeCP2 (methyl-CpG-binding protein 2) and Kaiso. At present,
MeCP2 have two biologically active isoforms called MeCP2E1
FIGURE 1 | Schematic diagram: DNA methylation in gene
transcriptional regulation. DNA methylation is mediated by Dnmts, which is
recruited by MBDs and form transcription repressor complexes together with
co-repressors (co-rep) and HDACs, and induces transcriptional inhibition.
Demethylation is mediated by TETs, which can catalyze oxidation of 5mC to
5-hydroxymethylcytosine (5hmC), and finally leads to disassembly of the
repressor complexes and gene transcriptional activation. MBDs,
methyl-binding domain proteins; Dnmts, DNA methyltransferases; HDACs,
histone deacetylase; Co-Rep, co-repressors; TETs, the ten-eleven
translocases; Gadd45β, growth arrest and DNA damage 45-beta.
and MeCP2E2 (Olson et al., 2014). Dnmts isoforms include
Dnmt1, which maintains the methylation on the genes, and
Dnmt3a and Dnmt3b for de novo establishment of DNA
methylation (reviewed in Houston et al., 2013; Smith and
Meissner, 2013). Cytosine methylation of promoter regions
usually represses gene transcription (Figure 1). Conversely,
demethylation is the process which removes a methyl group
(CH3) from 5mC, finally a hydrogen atom is added to
the site, resulting in a net loss of one carbon and two
hydrogen atoms. The ten-eleven translocases (TETs) family
of methylcytosine dioxygenases including TET1–3, collaborate
with DNA damage 45-beta (Gadd45β), Dnmts and HDACs, to
catalyze oxidation of 5mC to 5-hydroxymethylcytosine (5hmC),
thus promoting DNA demethylation (reviewed in Chen and
Riggs, 2011).
In post-mortem brains of patients with SZ, DNA methylation
has been assayed for a number of genes mainly expressed in
neurons, namely, Reelin, catechyl-O-methyltransferase (COMT),
OPRM (opioid receptor, mu), the serotonin-2A receptor gene
(HTR2A), brain derived neurotrophic factor (BDNF) and
arachidonate 5-lipoxygenase (ALOX5; reviewed in Grayson and
Guidotti, 2013). Research has reported an approximately twofold
increase of SAM level in SZ (Guidotti et al., 2007). In addition,
other researchers have reported that SAM levels regulate the
DNA methylome of Schwann cells, which are myelination glial
cells in the PNS (Varela-Rey et al., 2014). Furthermore, it
was also found that there was a higher expression of Dnmt1
and Dnmt3a in SZ than patients without SZ (Guidotti et al.,
2007; Zhubi et al., 2009). Besides neurons, Dnmt1, Dnmt3a and
Dnmt3b are also expressed in glial cells (Feng et al., 2005).
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 December 2015 | Volume 9 | Article 451
Chen et al. Glial DNA Methylation in Schizophrenia
Dnmt3a-deficient NSCs tend to differentiate into astrocytes and
oligodendrocytes as a result of demethylation of glial genes
(Wu et al., 2012b). This data suggests a potential role of DNA
methylation in glial cells which may partially explain the etiology
of SZ. Moreover, evidence has shown that abnormal glial cells,
such as astrocyte or oligodendrocyte dysfunction conjunction
with myelin deficits occur in white matter. Interestingly, these
changes are thought to be the result of their DNA methylated
status changes in SZ (Iwamoto et al., 2005, 2006; Wockner et al.,
2014).
DNA Methylation in Oligodendrocytes
Studies of Dnmt3a knockout NSCs indicates that Dnmt3amay be
involved in regulating fate determination of the oligodendroglial
lineage (Table 1). In Dnmt3a-deficient NSCs, the methylation
levels of oligodendroglial differentiation related genes such as
PDGFRα, Olig1, Sox10, MBP, Id2, Id4, Nkx2.2 and Nkx6.2 are
decreased, which results in up-regulation of these genes and
enhanced generation of oligodendroglial cells (Wu et al., 2010,
2012b). In addition, other researchers have shown that inMeCP2
null mice the loss of MeCP2 in the oligodendrocyte lineage cells
specifically resulted in more active behaviors with corresponding
severe hind limb clasping phenotypes. Moreover, these MeCP2
null mice displayed reduced expression of some myelin-related
proteins such as CNPase and MBP (Vora et al., 2010; Wu et al.,
2012a; Nguyen et al., 2013). On the other hand, Id2/4 was shown
to be demethylated during oligodendroglial differentiation,
which is mediated by protein arginine N-methyltransferase 5
(PRMT5; Huang et al., 2011).
In vitro studies involving OPC cultures have identified two
Hpa2 sites located at −1836 and −39 of the MAG gene that are
progressively demethylated during differentiation (Grubinska
et al., 1994), thereby altering the normal myelination process.
Recently, it was found that TET1-3 family members can regulate
the differentiation of OPCs. Specifically, TET2 is thought to
be critical for the expression of some important myelin genes,
such as MBP (Zhao et al., 2014; Table 1). Furthermore, the
level of 5hmC exhibited dynamic changes, indicating that the
combination of DNA methylation along with demethylation
may play an important role in the regulation of myelin gene
expression and OPCs’ differentiation (Zhao et al., 2014).
In SZ, Sox10 hyper-methylation was found to be correlated
with its reduced expression and oligodendrocyte dysfunction.
However, the CpG island of Olig2 and the methylated
state of MOBP, which encodes the structural protein in
mature oligodendrocytes, is rarely methylated in normal
brains (Iwamoto et al., 2005, 2006; Wockner et al., 2014).
Recent investigations on the corpus callosum following the
administration of cocaine showed a change in DNA methylation
at the promoter region of the Sox10 gene. However, the
methylated state of the myelin proteins such as MBP or PLP1 was
not affected (Nielsen et al., 2012).
Methylation has also been shown to be involved in myelin
protein integrity. For example, MBP arginine methylation level
decreased following brain development, which is critical for
MBP synthesis. However, in rats exposed to arsenic, MBP
arginine methylation level was increased as compared to normal
controls (Chanderkar et al., 1986; Zarazua et al., 2010).Moreover,
methylation in the promoter of the peptidylarginine deiminase
2 (PAD2; a key enzyme which converts arginines of MBP into
citrullines) was decreased to one-third of normal control in white
matter of patients with multiple sclerosis (MS; Mastronardi et al.,
2007). Recently, transcriptional regulation of BDNF by MeCP2
was believed as a novel mechanism for re-myelination and/or
myelin repair involved in the treatment of MS (KhorshidAhmad
et al., 2015).
DNA Methylation in Astrocyte
Astrocytes are the most abundant glial cells which are known
to play crucial roles in brain development (Namihira and
Nakashima, 2013). Astrocytes are generated from NPCs at early-
gestational to mid-gestational stages. They are located in the
ventricular and subventricular zone in late gestation. During
astrocytogenesis, cytokine-induced activation of the janus kinase
(JAK)-signal transducer and activator of transcription (Stat)
pathway are necessary. Activated Stat3 binds the promoter of
Gfap gene to active gene expression, thus inducing NPCs to
differentiate into astrocytes (Namihira and Nakashima, 2013).
On embryonic day 11.5 (E11.5), the Stat3 binding site at the
promoter region of Gfap gene is highly methylated, causing
its expression silenced. However, on E14.5, the promoter of
Gfap gene is demethylated thereby promoting its expression
(Takizawa et al., 2001; Hatada et al., 2008). In addition to the
promoter, the exon 1 of Gfap gene can also be modified by
methylation. MeCP2E1, an isoform of MeCP2, binds to exon 1
of Gfap gene to suppress Gfap gene expression (Tsujimura
et al., 2009). Moreover, under its ectopic expression, MeCP2
can prevent Gfap transcription and astrocytic differentiation
from NSCs, even in the presence of astrocytic induced cytokine
(Urayama et al., 2013).
As exposed to bromo-deoxyduridene (BrdU) or azacytidine,
Gfap is demethylated and this induces astrocytic differentiation
from NSCs (Schneider and d’Adda di Fagagna, 2012). Several
other targets have been linked to the demethylation of the
Gfap promoter. Specifically, Notch signaling, the hypoxia-
inducible factor 1a (HIF1α), Old astrocyte specifically induced
substance (OASIS), the murine homologs of chicken ovalbumin
upstream promoter transcription factors I and II (COUP-
TFI/II) are typical target molecules that contribute to the
demethylation of the Gfap promoter (Naka et al., 2008; Mutoh
et al., 2012; Saito et al., 2012). Interestingly, the CpG sites
in Gfap gene promoter are heavily methylated in microglia,
while demethylated in astrocytes (Barresi et al., 1999). Without
methylation, histone modifications by H3K9me3 or H3K27me3
are not sufficient for activation of Stat3-binding site in the
Gfap promoter region in NSCs. These facts indicate that
DNA methylation plays a critical role in deciding the timing
of astrocytogenesis (Urayama et al., 2013). In addition, the
gene of S100β is also hypo-methylated during astrocytogenesis
on E11.5. It has also been shown that following chemical
exposure of ethanol, the protein levels of Dnmt3a and activity
of Dnmts become increased, causing demethylation of the tissue
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TABLE 1 | DNA methylated sate and glia related gene expression.
Gene Methylated state Expression Reference Condition
MAG Demethylated Increase Grubinska et al. (1994) Differentiation of culture OLs
MBP Demethylated Increase Wu et al. (2010) Dnmt3a−/− NSCs
Methylated of arginine Increase Nguyen et al. (2013) Development
Olig1 Demethylated Increase Wu et al. (2010) Dnmt3a−/− NSCs
Sox10 Hypermethylated Decrease Iwamoto et al. (2005, 2006)
and Wockner et al. (2014)
Schizophrenia
Decrease Nielsen et al. (2012) Cocaine exposure
PAD2/4 Decreased methylation Increase Mastronardi et al. (2007) Multiple sclerosis (MS)
Id2/4 Demethylated Increase Huang et al. (2011) NSCs differentiation
Increase Wu et al. (2010) Dnmt3a−/− NSCs
GFAP Demethylated Increase Takizawa et al. (2001) and Hatada
et al. (2008)
Gliogenesis
MeCP2 E1 bind to exon 1 of Gfap — Tsujimura et al. (2009) NSCs
S100β Demethylated Increase Hatada et al. (2008) Gliogenesis
EAAT2 Hypermethylated Decrease Zschocke et al. (2007) Glioma cell lines
tPA Demethylated Increase Zhang et al. (2014) Ethanol exposure
Kir4.1 Hypermethylated Decrease Nwaobi et al. (2014) Ischemic, injury, epilepsy,
and Alzheimer
MCT4 Hypermethylated Decrease Liu et al. (2014) Temporal lobe epilepsy
plasminogen activator (tPA) promoter and resulting in increased
expression in of these proteins in astrocytes (Zhang et al.,
2014).
Recent research has also shown that hypo-methylation
in astrocytes alters the expression of EAAT2, a family
member of glutamate transporters (Zschocke et al., 2007).
Interestingly, researchers have also reported that the down-
regulation of MeCP2 did not affect cell morphology, growth,
and cytotoxic reaction, but reduced expression of EAAT1/2
in astrocytes (Okabe et al., 2012). However, MeCP2 deficiency in
astrocytes has been shown to cause significant abnormalities in
BDNF regulation, cytokine production, and neuronal dendritic
induction via non-cell-autonomous mechanism on gap junction
(Maezawa et al., 2009). In SZ, the expression of EAAT2 was
significantly reduced in astrocytes, suggesting that abnormal
methylation status of EAAT1/2 in astrocytes may be involved in
its pathogenesis (Katsel et al., 2011a).
DNA Methylation in Glial Cells and Other
Mental Disorders
Rett syndrome (RTT) is a childhood white matter disorder
caused by mutations in MeCP2. It is an X-linked neuro-
developmental disorder featured by autism and severe mental
retardation and neurological dysfunction in females. Although
RTT is generally attributed to be a primary neuronal dysfunction,
it has recently been shown that astrocytes, oligodendrocytes and
microglia also contribute to RTT pathophysiology (Maezawa
et al., 2009; Derecki et al., 2012; Nguyen et al., 2013). MeCP2
deficiency results in oligodendrocytes and astrocytes abnormities
as mentioned above. MeCP2-null microglia was shown to
produce a fivefold higher level of glutamate. As such, the
blockage of microglial glutamate released by gap junction and
glutamate receptor antagonists attenuated the neurotoxicity
associated with MeCP2-null microglia (Maezawa and Jin, 2010).
Genome-wide methylation map has identified significant
changes in methylation of astrocytic markers such as
Gfap, aldehyde dehydrogenase 1 family, member L1
(ALDH1L1), SOX9, glutamate-ammonia ligase (GLUL), the
sodium/phosphate cotransporters NaPi-IIc (SCL34A3), gap
junction alpha 1 (GJA1) and gap junction beta 6 (GJB6), brain-
enriched guanylate kinase-associated protein (BEGAIN) and
glutamate receptor ionotropic kainate 2 (GRIK2). These markers
can serve as functional candidates involved in the clinical
screening of patients for susceptibility to SZ (Nagy et al., 2015).
In addition, the expression pattern of these markers has been
suggested to correlate with changes in depression that is often
suffered by patients with SZ. For these reasons, the significant
differences in the methylation patterns specific to astrocytic
dysfunction are now thought to be associated with depressive
psychopathology (Nagy et al., 2015).
Kir4.1 is a glial-specific potassium (K+) channel which is
essential for the development of the CNS. As such, decreased
Kir4.1 expression is associated with Dnmt1-mediated DNA
hyper-methylation inmedical conditions such as ischemic injury,
epilepsy, and Alzheimer’s disease (Nwaobi et al., 2014). In
astrocytes, hypermethylation of monocarboxylate transporter 4
(MCT4) gene results in a significantly lower expression ofMCT4,
which subsequently leads to neuronal hyper-excitability and
epileptogenesis in temporal lobe epilepsy patients (Liu et al.,
2014).
CLINICAL IMPLICATIONS AND FUTURE
DIRECTIONS
Based on the comprehensive review of the current literature, we
have identified the importance of abnormal DNA methylation
and demethylation in psychiatric disorders such as SZ.
Specifically, research has identified aberrant methylation, growth
arrest and DNA damage 45-beta (Gadd45β), as part of the
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DNA-demethylation pathway component, whose expression
was increased by nearly threefold in SZ (Matrisciano et al.,
2011). DNA methylation combineds with histone deacetylation
regulate gene expression and represent two key focal points
for epigenetic therapeutic interventional strategies for SZ. As
such, evidence shows that adjunctive therapy for SZ may
be more effective by combining demethylation with histone
deacetylation (Dong et al., 2008, 2010). Because aberrant DNA
methylation and histone deacetylation patterns are potentially
irreversible, it has been suggested that therapy based on
inhibiting DNA demethylation and histone deacetylation may
serve as novel intervention strategies for early stage SZ. For
example, when SZ-like mice being treated with antipsychotic
drug clozapine and HDAC inhibitor VPA, Gadd45β expression
can be activated and bind specific promoter regions of Reelin
and GAD67 to cause hypomethylation, and thereby be beneficial
for SZ treatment (Dong et al., 2008, 2010; Matrisciano et al.,
2011).
Since glial abnormalities are thought to be key players in
SZ pathology, new strategies that target the glial cells may be
beneficial in the treatment of SZ (Takahashi and Sakurai, 2013;
Guidotti and Grayson, 2014; Bernstein et al., 2015). Furthermore,
since DNA methylation has an important role in regulating
expression of glial genes DNA methylation (Table 1), studies
involving more glial candidate genes should be conducted
to elucidate their effects in the underlying pathogenesis of
SZ. Henceforth, the advanced understanding of the specific
mechanisms involving DNA methylation in regulating glial
genesis and their pathological roles in SZ provide new insights
into interventional treatment strategies for SZ and other related
illnesses.
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